ArticlePLoS neglected tropical diseases2010
Identification of attractive drug targets in neglected-disease pathogens using an in silico approach.
Article in PLoS neglected tropical diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 157 citations in OpenAlex.
- New hit compounds againstAntimicrobial agents and chemotherapy · 2026Article
- Evaluating the evolutionary relationship of TATA binding protein (TBP) with various folding patterns of protein domains using support vector machine (SVM).Scientific reports · 2026Article
- Protection Elicited by Glutamine Auxotroph ofVaccines · 2025Article
- Identification and Functional Annotation of Hypothetical Proteins of Pan-Drug-ResistantBioinformatics and biology insights · 2024Article
- Pathogenomic in silico approach identifies NSP-A and Fe-IIISBP as possible drug targets in Neisseria Meningitidis MC58 and development of pharmacophores as novel therapeutic candidates.Molecular diversity · 2023Article
- Targeting trypanosomes: how chemogenomics and artificial intelligence can guide drug discovery.Biochemical Society transactions · 2023Review
- Article
- The Use of AlphaFold forFrontiers in cellular and infection microbiology · 2022Article
- Deletion of Glutamine Synthetase Gene Disrupts the Survivability and Infectivity ofFrontiers in cellular and infection microbiology · 2021Article
- Putative Drug Target Identification in Tinea Causing Pathogen Trichophyton rubrum Using Subtractive Proteomics Approach.Current microbiology · 2020Article
- Genome-scale metabolic models highlight stage-specific differences in essential metabolic pathways in Trypanosoma cruzi.PLoS neglected tropical diseases · 2020Article
- In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum.Biomedica : revista del Instituto Nacional de Salud · 2020Article
- Targeting tRNA-synthetase interactions towards novel therapeutic discovery against eukaryotic pathogens.PLoS neglected tropical diseases · 2020Article
- TDR Targets 6: driving drug discovery for human pathogens through intensive chemogenomic data integration.Nucleic acids research · 2020Article
- Leishmanicidal Potential of Hardwickiic Acid Isolated FromFrontiers in pharmacology · 2020Article
- The Novel Serine/Threonine Protein Kinase LmjF.22.0810 fromBiomolecules · 2019Article
- Human Migration and the Spread of the Nematode Parasite Wuchereria bancrofti.Molecular biology and evolution · 2019Article
- Identification of small molecule enzyme inhibitors as broad-spectrum anthelmintics.Scientific reports · 2019Article
- Targeting the Pentose Phosphate Pathway: Characterization of a New 6PGL Inhibitor.Biophysical journal · 2018Article
- In silico repositioning of approved drugs against Schistosoma mansoni energy metabolism targets.PloS one · 2018Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increased sequencing of pathogen genomes and the subsequent availability of genome-scale functional datasets are expected to guide the experimental work necessary for target-based drug discovery. However, a major bottleneck in this has been the difficulty of capturing and integrating relevant information in an easily accessible format for identifying and prioritizing potential targets. The open-access resource TDRtargets.org facilitates drug target prioritization for major tropical disease pathogens such as the mycobacteria Mycobacterium leprae and Mycobacterium tuberculosis; the kinetoplastid protozoans Leishmania major, Trypanosoma brucei, and Trypanosoma cruzi; the apicomplexan protozoans Plasmodium falciparum, Plasmodium vivax, and Toxoplasma gondii; and the helminths Brugia malayi and Schistosoma mansoni. METHODOLOGY/PRINCIPAL
findingsHere we present strategies to prioritize pathogen proteins based on whether their properties meet criteria considered desirable in a drug target. These criteria are based upon both sequence-derived information (e.g., molecular mass) and functional data on expression, essentiality, phenotypes, metabolic pathways, assayability, and druggability. This approach also highlights the fact that data for many relevant criteria are lacking in less-studied pathogens (e.g., helminths), and we demonstrate how this can be partially overcome by mapping data from homologous genes in well-studied organisms. We also show how individual users can easily upload external datasets and integrate them with existing data in TDRtargets.org to generate highly customized ranked lists of potential targets. CONCLUSIONS/SIGNIFICANCE: Using the datasets and the tools available in TDRtargets.org, we have generated illustrative lists of potential drug targets in seven tropical disease pathogens. While these lists are broadly consistent with the research community's current interest in certain specific proteins, and suggest novel target candidates that may merit further study, the lists can easily be modified in a user-specific manner, either by adjusting the weights for chosen criteria or by changing the criteria that are included.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.